Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

About Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals logoXenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENE
  • CUSIP: N/A
  • Web: www.xenon-pharma.com
Capitalization:
  • Market Cap: $60.29 million
  • Outstanding Shares: 17,996,000
Average Prices:
  • 50 Day Moving Avg: $3.55
  • 200 Day Moving Avg: $5.50
  • 52 Week Range: $2.85 - $9.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.99
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $1.22 million
  • Price / Sales: 47.20
  • Book Value: $3.18 per share
  • Price / Book: 1.01
Profitability:
  • EBIDTA: ($26,400,000.00)
  • Net Margins: -2,237.36%
  • Return on Equity: -44.85%
  • Return on Assets: -42.36%
Debt:
  • Current Ratio: 16.47%
  • Quick Ratio: 16.47%
Misc:
  • Average Volume: 79,011 shs.
  • Beta: 1.46
  • Short Ratio: 1.52
 
Frequently Asked Questions for Xenon Pharmaceuticals (NASDAQ:XENE)

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Thursday, November, 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.08. The company earned $0.41 million during the quarter, compared to analyst estimates of $0.40 million. Xenon Pharmaceuticals had a negative net margin of 2,237.36% and a negative return on equity of 44.85%. View Xenon Pharmaceuticals' Earnings History.

When will Xenon Pharmaceuticals make its next earnings announcement?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Xenon Pharmaceuticals.

Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?

5 analysts have issued twelve-month target prices for Xenon Pharmaceuticals' stock. Their forecasts range from $5.00 to $20.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $12.50 in the next twelve months. View Analyst Ratings for Xenon Pharmaceuticals.

What are analysts saying about Xenon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (7/1/2017)
  • 2. Jefferies Group LLC analysts commented, "Several key ph.II readouts, XEN801 in acne (March) and TV-45070 in post-herpetic neuralgia (PHN) (mid-year), should provide sig. NT stock catalysts. Based on our analyses, our view is their acne and pain programs collectively could generate $1.5B cumulative future royalties/milestones if successful, and a valuation we believe overly discounts the promise of their pipeline and platform, we view reward/risk favorably. Assuming at Buy with $13 PT." (3/13/2017)

Who are some of Xenon Pharmaceuticals' key competitors?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:

  • Michael M. Tarnow, Chairman of the Board
  • Ian C. Mortimer MBA., CPA., CMA., Chief Financial Officer, Chief Operating Officer
  • James R. Empfield, Senior Vice President - Drug Discovery
  • Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development
  • Charles M. Cohen Ph.D., Vice President - Biology
  • Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development
  • Karen G. Corraini J.D., General Counsel and Corporate Secretary
  • Simon Neil Pimstone M.B., ChB., Ph.D., President, Chief Executive Officer, Director
  • Mohammad Azab, Director
  • Steven R. Gannon, Director

How do I buy Xenon Pharmaceuticals stock?

Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $3.20.


MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Xenon Pharmaceuticals (NASDAQ:XENE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50 (290.63% upside)

Analysts' Ratings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/28/2017Jefferies Group LLCLower Price TargetBuy$8.00 -> $5.00MediumView Rating Details
6/27/2017Canaccord GenuityReiterated RatingBuy$5.00LowView Rating Details
12/22/2016Bloom BurtonInitiated CoverageBuy$14.50N/AView Rating Details
10/21/2016Stifel NicolausInitiated CoverageBuy$18.00N/AView Rating Details
9/26/2016GuggenheimInitiated CoverageBuy -> Buy$20.00N/AView Rating Details
9/24/2015SEB Equity ResearchReiterated RatingPositiveN/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)
Earnings by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Earnings History by Quarter for Xenon Pharmaceuticals (NASDAQ XENE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.39)N/AView Earnings Details
3/8/201712/31/2016($0.42)($0.32)$0.40 million$0.38 millionViewListenView Earnings Details
11/3/2016Q316($0.43)($0.51)$0.40 million$0.41 millionViewListenView Earnings Details
8/3/2016Q216($0.48)($0.42)$0.50 million$0.41 millionViewN/AView Earnings Details
5/10/2016Q116($0.21)($0.23)$3.30 million$0.60 millionViewListenView Earnings Details
3/8/2016Q415($0.16)($0.27)$4.90 million$3.23 millionViewListenView Earnings Details
11/10/2015Q315($0.02)($0.27)$4.65 million$4.29 millionViewListenView Earnings Details
8/10/2015Q215($0.16)($0.07)$4.90 million$4.05 millionViewListenView Earnings Details
5/12/2015Q115$0.14($0.30)$4.65 million$4.00 millionViewListenView Earnings Details
3/12/2015Q4($0.09)$1.57$5.10 million$4.43 millionViewListenView Earnings Details
12/15/2014$0.41$1.69$5.00 million$13.19 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)
2017 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.29)($0.29)($0.29)
Q4 20171$0.32$0.32$0.32
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 56.01%
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/27/2017Value Fund L P BiotechnologyInsiderBuy85,461$4.00$341,844.00View SEC Filing  
6/22/2017Value Fund L P BiotechnologyInsiderBuy20,411$4.00$81,644.00View SEC Filing  
6/19/2017Value Fund L P BiotechnologyInsiderBuy26,408$3.84$101,406.72View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy358,698$3.81$1,366,639.38View SEC Filing  
12/15/2016Frank A HollerDirectorSell30,000$7.85$235,500.00View SEC Filing  
8/19/2016Frank A HollerDirectorSell11,938$7.65$91,325.70View SEC Filing  
8/18/2016Frank A HollerDirectorSell18,062$7.93$143,231.66View SEC Filing  
6/24/2016Ian MortimerCFOBuy5,300$6.22$32,966.00View SEC Filing  
9/24/2015Y. Paul GoldbergVPSell22,149$8.88$196,683.12View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Xenon Pharmaceuticals (NASDAQ:XENE)
Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
Source:
DateHeadline
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) to Release Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:32 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $380,000.00
www.americanbankingnews.com - July 19 at 3:02 PM
americanbankingnews.com logoZacks: Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - July 17 at 11:29 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:57 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) PT Lowered to $5.00
www.americanbankingnews.com - July 2 at 2:34 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - July 1 at 9:28 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) to Post Q3 2017 Earnings of ($0.29) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 30 at 8:06 AM
americanbankingnews.com logoValue Fund L. P. Biotechnology Purchases 85,461 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 29 at 7:47 PM
americanbankingnews.com logoJefferies Group Weighs in on Xenon Pharmaceuticals Inc.'s Q4 2017 Earnings (XENE)
www.americanbankingnews.com - June 29 at 9:54 AM
finance.yahoo.com logoTeva/Xenon Nerve Pain Candidate Fails in Phase II Study
finance.yahoo.com - June 29 at 8:07 AM
finance.yahoo.com logoXenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
finance.yahoo.com - June 28 at 3:32 AM
americanbankingnews.com logoInsider Buying: Xenon Pharmaceuticals Inc. (XENE) Insider Acquires 20,411 Shares of Stock
www.americanbankingnews.com - June 23 at 10:34 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) Expected to Post Quarterly Sales of $450,000.00
www.americanbankingnews.com - June 23 at 5:52 PM
americanbankingnews.com logo Brokerages Anticipate Xenon Pharmaceuticals Inc. (XENE) to Announce -$0.38 EPS
www.americanbankingnews.com - June 21 at 7:34 AM
americanbankingnews.com logoValue Fund L. P. Biotechnology Purchases 26,408 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 20 at 10:20 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc. (XENE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 13 at 7:45 AM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Xenon Pharmaceuticals Inc. (XENE)
www.americanbankingnews.com - June 12 at 8:28 AM
americanbankingnews.com logoInsider Buying: Xenon Pharmaceuticals Inc (XENE) Insider Acquires 358,698 Shares of Stock
www.americanbankingnews.com - June 8 at 7:12 PM
finance.yahoo.com logoXenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 2:34 AM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 3 at 2:34 AM
americanbankingnews.com logo$450,000.00 in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - May 28 at 10:46 AM
americanbankingnews.com logoZacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:58 PM
americanbankingnews.com logoAnalysts Set Expectations for Xenon Pharmaceuticals Inc's FY2017 Earnings (XENE)
www.americanbankingnews.com - May 12 at 11:44 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - May 11 at 4:46 PM
americanbankingnews.com logoJefferies Group Analysts Cut Earnings Estimates for Xenon Pharmaceuticals Inc (XENE)
www.americanbankingnews.com - May 11 at 3:40 PM
finance.yahoo.com logoEdited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:19 PM
finance.yahoo.com logoInvestor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 8:14 PM
finance.yahoo.com logoXenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 8:14 PM
marketbeat.com logoXenon Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 7:04 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:20 AM
americanbankingnews.com logo Analysts Expect Xenon Pharmaceuticals Inc (XENE) Will Announce Quarterly Sales of $450,000.00
www.americanbankingnews.com - May 4 at 12:02 PM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Earns Daily News Impact Rating of 0.14
www.americanbankingnews.com - May 4 at 8:24 AM
finance.yahoo.com logoNuventra founder inks deal for new venture that could be worth as much as $49 million
finance.yahoo.com - April 29 at 2:42 AM
finance.yahoo.com logoXenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 29 at 2:42 AM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Earning Somewhat Critical Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 8:32 AM
finance.yahoo.com logoXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
finance.yahoo.com - April 26 at 8:10 AM
feeds.benzinga.com logoXenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
feeds.benzinga.com - April 26 at 7:01 AM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - April 25 at 3:14 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 24 at 9:43 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Short Interest Update
www.americanbankingnews.com - April 22 at 5:17 PM
americanbankingnews.com logoXenon Pharmaceuticals (XENE) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 7:50 AM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - April 11 at 2:12 PM
americanbankingnews.com logoXenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 12:38 PM
rttnews.com logoXenon Pharmaceuticals Inc. (XENE) Plunged To A New Low After Study Failed
www.rttnews.com - March 27 at 8:01 PM
streetinsider.com logoXenon Pharmaceuticals (XENE) Says XEN801 Missed Efficacy Endpoints in Phase 2 Trial in Patients with Moderate to Severe Acne
www.streetinsider.com - March 24 at 3:47 PM
rttnews.com logoXenon Pharmaceuticals Inc. (XENE) Has Plunged To A New Low After Study Failed
www.rttnews.com - March 24 at 3:47 PM
finance.yahoo.com logoXenon Pharmaceuticals' acne drug fails mid-stage study
finance.yahoo.com - March 24 at 3:47 PM
finance.yahoo.com logoShares slump after Xenon Pharmaceuticals abandons acne drug
finance.yahoo.com - March 24 at 3:47 PM

Social

Chart

Xenon Pharmaceuticals (XENE) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff